tradingkey.logo
搜尋

PharmaCyte Biotech Inc

PMCB
添加自選
0.715USD
-0.026-3.51%
收盤 07/02, 13:00美東報價延遲15分鐘
7.68M總市值
虧損本益比TTM

PharmaCyte Biotech Inc

0.715
-0.026-3.51%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-3.51%

5天

-7.11%

1月

-1.43%

6月

-3.12%

今年開始到現在

-1.24%

1年

-35.59%

關鍵數據
0.756今開
0.770最高
55.65K成交量
虧損本益比TTM
--本益比動
--股利TTM
0.52%換手率
0.741昨收
0.715最低
34.15K成交額
0.33本益比靜
0.20市淨率
0.00%股息率 TTM
-6.58%ROA
1.51052週最高
1.20量比
23.36M淨利潤
10.74M總股本
-0.8906每股盈餘TTM
0.50Beta
-19.01%ROE
0.63052週最低
7.42%振幅
--毛利率
7.68M總市值
0.38回報/風險
5.59%風險率

TradingKey PharmaCyte Biotech Inc股票評分

單位: USD 更新時間: 2026-07-02

操作建議

PharmaCyte Biotech Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名219/387位。機構持股佔比非常高,中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

PharmaCyte Biotech Inc評分

相關信息

行業排名
219 / 387
全市場排名
439 / 4565
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看好

PharmaCyte Biotech Inc亮點

亮點風險
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
業績轉盈
公司業績轉盈,最新年度盈利美元
估值合理
公司最新PE估值-0.80,處於3年歷史合理位
機構加倉
最新機構持股1.07M股,環比增加24.50%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉0.00股

分析師目標

基於 0 分析師
--
評級
--
目標均價
--
漲幅空間

PharmaCyte Biotech Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

PharmaCyte Biotech Inc簡介

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
公司代碼PMCB
公司PharmaCyte Biotech Inc
CEOSilverman (Joshua N)
網址https://pharmacyte.com/

常見問題

PharmaCyte Biotech Inc(PMCB)的當前股價是多少?

PharmaCyte Biotech Inc(PMCB)的當前股價是 0.71。

PharmaCyte Biotech Inc 的股票代碼是什麼?

PharmaCyte Biotech Inc的股票代碼是PMCB。

PharmaCyte Biotech Inc股票的52週最高點是多少?

PharmaCyte Biotech Inc股票的52週最高點是1.51。

PharmaCyte Biotech Inc股票的52週最低點是多少?

PharmaCyte Biotech Inc股票的52週最低點是0.63。

PharmaCyte Biotech Inc的市值是多少?

PharmaCyte Biotech Inc的市值是7.68M。

PharmaCyte Biotech Inc(PMCB)股票的每股收益(EPS TTM)是多少

PharmaCyte Biotech Inc(PMCB)股票的每股收益(EPS TTM)是3.19。